Navigation Links
DCR Set - Angled

ProductsDCR Set - Angled
Company Hurricane Medical
Item DCR Set - Angled
Features 
Description For surgical treatment, repair and irrigation of the nasolacrimal system. Angled 45 degrees 13mm from end. Stainless steel probes, 20G x 1 3/4in (.90 x 45cm) Silicone rod, length 13 3/4in (40cm), Diameter.032in (.80mm)
Info Hurricane Medical
Customer Service: (877) 446-1444

Related medicine products :

1. Osher Nucleus Manipulator - Angled
2. Lester Lens Manipulator Angled
3. Olk Angled Retinal Pick - 110 Degree
4. Olk Angled Retinal Pick - 150 Degree
5. Olk Angled Retinal Pick - 130 Degree
6. Olk Angled Retinal Spatula - 110 Degree
7. Olk Angled Retinal Spatula - 150 Degree
8. Olk Angled Retinal Spatula - 130 Degree
9. Knapp Eye Speculum - Angled
10. Lieberman Open Wire Speculum Angled 45 Degree
11. Lieberman Wire Speculum Angled
TAG: DCR Set Angled
The Mago® Plus Automated EIA Analyzer is a fully automated, integrated ELISA system. Together, with immunosimplicity® reagents, the Mago® Plus provides a flexible, integrated solution
The LABOTECH is an automated microplate analyzer capable of fully automating immunoenzymatic microplate techniques. Open architecture design makes the system adaptable to many manufacturers' micropla
The Titertek MAP-C2 is designed for high throughput microplate processing. The heart of the instrument is the S60 Stacker that handles up to 60 microplates in two removable magazines. The MAP-C2 base
The Rapidpoint 400/405 instrument is a point-of-care blood gas analyzer that's fast, easy to operate and reliable.
Medicine Products:
(Date:11/21/2008)... Conney Safety,s New Website is Simple, Po... Shopping for Safety Products Easier than Ever , ...er 21, 2008 -- Conney Safety Products is proud to ...om - has been completely redesigned using state-o...ore efficient and features a clean new layout to m...
(Date:11/20/2008)...f a macrolide antibiotic may reduce the frequency ...re chronic obstructive pulmonary disease (COPD) by...d study. , "Our results show a significant effe...ation frequency and severity with moderate to seve...A. R. Seemungal, Ph.D., and Jadwiga Wedzicha, M.D....
(Date:11/20/2008)... Catherine T. MacArthur Foundation is creating a n...rica prepare for the challenges and opportunities ...next decade, the United States will become an agin... age 60 will outnumber those under age 15. Althou...sequent decades, we are not well prepared to deal ...
(Date:11/20/2008)...C, 19 NOVEMBER 2008 The consumption of illicit or...ries worldwide and contributes significantly to th...ort released today by the International Center for...e use of noncommercial alcohol, defined as traditi...mited local trade and counterfeit or unregistered ...
Breaking Medicine News(10 mins):Health News:Conney Safety Products, Leader in Safety Equipment and Supplies, Launches New Website 2Health News:Long-term antibiotics reduce COPD exacerbations, raise questions 2Health News:Long-term antibiotics reduce COPD exacerbations, raise questions 3Health News:New MacArthur network to examine impact of aging society 2Health News:Report finds extensive use of illicit alcohol 2
... rich source of live-saving stem cells, seven bank...ia, and the first of the series will open in Gurga...between Cryobanks International, a US body, and R.... Ravi Jaipuria, will invest Rs.1 billion to build ...
... study has discovered a connection between genetic...cies play a significant role in the use of drugs./...rch, said "This is the first study to show the im...re/country (Norway) with rather low rates of drug ...
... trouble falling or staying asleep, you're not alo...rly seven out of 10 Americans say they frequently/...that may be cause for concern, says Henry Raroque,...p specialist on the medical staff at Baylor Region...
...rnment has planned to outlaw sex selection of babi... of embryology regulation.// Health Minister Caro...o introduce a "clear and specific ban" on the use ...by, saying that allowing such practices among pare...
Other Medicine News:Health News:First Cord Blood Bank in North India to be Opened in Gurgaon 2
(Date:11/20/2008)...LLA, Calif., Nov. 20 Dus..., announced today that it has submitted its,pivot...ew under a Special,Protocol Assessment (SPA) proc...(FDA). , Subject to securing an agreement w...prospective, double-blind, placebo-controlled and ...
(Date:11/20/2008)...N, Nov. 20 PAREXEL Inter...global biopharmaceutical services provider, today ...ru to provide regulatory consulting and clinical r...u office, PAREXEL now has locations throughout fiv...rica, which also include Argentina, Brazil, Chile,...
(Date:11/19/2008)...AND OAKS, Calif., Nov. 19 /PRNewswire-FirstCall/ -...eda Oncology Company, a subsidiary of,Takeda Phar...unced that,enrollment in the Phase 3 MONET1 trial...th paclitaxel and carboplatin for the first-line t...NSCLC) has been temporarily suspended,following a...
(Date:11/19/2008)...OCHELLE, N.Y., Nov. 19 Biotech sci...ogies to toxicology research to better understand ...of organ systems, reports Genetic Engineering &am...y interested in figuring out a new compound,s mech...tive toxicology technique, according to the Novemb...
Breaking Medicine Technology:Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7GEN Reports on the Trend Toward Predictive Toxicogenomics 2Stereotaxis Appoints David Burkhardt M D as Chief Medical Officer 2630 1Stereotaxis Appoints David Burkhardt M D as Chief Medical Officer 2630 2Stereotaxis Appoints David Burkhardt M D as Chief Medical Officer 2630 3YM BioSciences provides update on AeroLEF 28TM 29 clinical development program 2628 1YM BioSciences provides update on AeroLEF 28TM 29 clinical development program 2628 2YM BioSciences provides update on AeroLEF 28TM 29 clinical development program 2628 3Speedy Procedures Demonstrate Excitement and Continued Interest in Novel Multi Electrode Ablation System 9678 1Speedy Procedures Demonstrate Excitement and Continued Interest in Novel Multi Electrode Ablation System 9678 2Matrixx Initiatives Inc Updates 2007 2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook 9674 1Matrixx Initiatives Inc Updates 2007 2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook 9674 2Matrixx Initiatives Inc Updates 2007 2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook 9674 3Matrixx Initiatives Inc Updates 2007 2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook 9674 4
...ublished in the Journal of Clinical Oncology -, NE...sults from a,Phase II study - which will be publis... Clinical Oncology (JCO) and are now,available as ...f=,"http://www.jco.org/">www.jco.org - demonstrat... investigational,compound, has activity in patient...
...July 05, 2007 /PRNewswire/ -- Results from,the pri...bel, Phase,3 study showed that 77 percent of treat...ISTA(TM) (darunavir) 600 mg tablets with,100 mg ri...d,background regimen (OBR) of antiretroviral (ARV)...s/mL at week 48, compared to 68,percent of patient...
Other Medicine Technology:Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 2Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 3Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8